RxDoctor Payments Data

Simon Blanc, MD

Hematology & Oncology · Miami Beach, FLNPI 1255683652

Payments from drug & device makers

$160,228in general payments, 2019–2025

Across 540 payments — averaging $296.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$43K
  • Bristol Myers Squibb$27K
  • Regeneron Healthcare Solutions, Inc.$19K
  • AstraZeneca$17K
  • Daiichi Sankyo Inc.$16K
  • Array Biopharma Inc$7K
  • plus $31K from 54 others

What the payments were for

  • Consulting fees$49,87731%
  • Speaking & faculty fees$77,68948%
  • Travel & lodging$18,76712%
  • Food & beverage$10,8507%
  • Education$2210%
  • Gifts$1,6281%
  • Other$1,1961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)74$42,568
Bristol Myers Squibb26$27,208
Regeneron Healthcare Solutions, Inc.14$19,210
AstraZeneca33$16,999
Daiichi Sankyo Inc.25$16,407
Array Biopharma Inc9$6,956
EMD Serono, Inc.16$6,503
Ipsen Biopharmaceuticals, Inc10$6,082
Sanofi6$4,333
Novartis67$3,427
Sobi, Inc6$3,318
Heron Therapeutics, Inc.2$1,622
Pfizer33$702
Merck23$495
E.r. Squibb & Sons, L.L.C.24$445
Genentech USA, Inc.16$302
GSK11$270
Tempus AI, Inc11$258
Amgen21$244
Coherus Oncology, Inc.2$211
Seagen Inc.6$201
Lilly USA, LLC9$181
Rigel Pharmaceuticals, Inc.4$173
Incyte Corporation8$171
AbbVie7$163
ASD Specialty Healthcare, LLC3$136
Tesaro, Inc.1$125
Eisai Inc.5$103
Pharmacyclics LLC, An Abbvie Company4$92
ADC Therapeutics America, Inc.3$81
Takeda Pharmaceuticals U.S.A., Inc.3$74
Adaptive Biotechnologies Corporation3$66
Pharmaessentia USA Corporation3$66
Astellas Pharma US Inc3$62
Boehringer Ingelheim3$60
Bayer3$57
Novocure Inc.2$54
Karyopharm Therapeutics Inc.2$51
Dendreon Pharmaceuticals LLC2$51
Stemline Therapeutics Inc.2$48
Azurity Pharmaceuticals, Inc.2$47
Puma Biotechnology, Inc.3$45
Exelixis Inc.2$44
Morphosys, US Inc.2$44
Pharmacosmos Therapeutics Inc.2$41
Taiho Oncology, Inc.2$41
Myriad Genetic Laboratories, Inc.2$37
Beone Medicines USA, Inc.1$32
Gilead1$30
Spectrum Pharmaceuticals Inc.2$26
Agios Pharmaceuticals, Inc.2$26
Fennec Pharmaceuticals, Inc.1$24
Tolmar Pharmaceuticals, Inc.1$23
Recordati_rare_diseases_inc.1$23
Jazz Pharmaceuticals Inc.1$22
Dova Pharmaceuticals1$21
Tersera Therapeutics LLC1$20
Syndax Pharmaceuticals, Inc.1$19
Legend Biotech USA Inc.1$16
Kyowa Kirin, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,228 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$36,418
Medicare patients
152
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$9,901
Prochlorperazine Maleate36$407
Dexamethasone17$333
Ondansetron OdtOndansetron25$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$702$9,90115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →